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OBJECTIVES: COPD represents a substantial burden on
health resources worldwide. Especially acute exacerba-
tions (AECB) are an increasing cause of morbidity, 
mortality and reduced quality of life. As a chronic 
disease COPD is a major target for disease management
programs (DMPs) in Germany, since providers and
patients may beneﬁt from structured treatment programs.
Here we report preliminary results regarding the effects
of a newly implemented DMP on COPD therapy.
METHODS: In 2001 a DMP for COPD, involving a
network of general practitioners, outpatient specialists
and clinicians, was implemented in the town of Lueden-
scheid, Germany, with about 81,000 inhabitants. The
only German COPD-DMP includes treatment guidelines
and a peer review group concept. COPD-patients are
involved by patient information, education about the
disease and reduction of risk factors (e.g. smoking cessa-
tion). To evaluate the DMP, an open, non-intervening
outcome study was set up. In this ongoing study, the
outcome in the DMP-group (Luedenscheid) will be com-
pared to a group in a town 70km apart without a DMP.
A total of 462 patients is enrolled into the study. For
assessment of the short term effects (0.5 years), partici-
pating physicians in Luedenscheid were interviewed
about the effectiveness of the different components of the
DMP and about an improvement in their treatment of
COPD-patients. RESULTS: 24 physicians were inter-
viewed. At this preliminary state, the majority of them
judged the regular peer review meetings (75% positive
answers) and the treatment guidelines (58% positive
answers) as efﬁcient factors of the DMP. An improvement
in COPD-management was seen by 54% of the physi-
cians. CONCLUSION: The ﬁrst German COPD-DMP set
up in Luedenscheid shows a tendency to improve COPD-
treatment. This may lead to decreased disease progres-
sion, enhanced quality of life and reduced health care
costs. Further preliminary and demographic data from
the evaluation study will be presented.
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OBJECTIVES: Asthma treatments have a good
beneﬁt/risk ratio. Recent recommendations from interna-
tional consensus have standardised asthmatic patients’
management methods (Gina 2002). Compliance with
these standards, however, remains low: a more global
management is required. Alliance Médica and a local
sickness fund (Eure Department) have launched a disease
management program, including education of patients
and training of doctors to improve the state of health of
patients suffering from asthma and reduce costs to the
community. METHODS: The assessment is based on 
a “before-after” study (respectively 18 and 12 months).
Two outcomes were assessed: control of the asthma and
the quarterly cost of follow-up. The deﬁnition of control
is based on the six criteria and thresholds from the 
Canadian asthma consensus report (1). The quarterly cost
is the sum of medical expenditure and production losses
for patients who had at least one follow-up consultation
during each period considered. RESULTS: Forty-three
doctors agreed to take part in the study, 32 of whom
returned the medical information electronically. Three
hundred and thirty eight patients were pre-included: 27
patients did not meet the inclusion criteria and 311 sub-
jects were eligible. Proportion of asthmatic patients con-
trolled over the 1-year period before the intervention was
equal to 52.6% of the patients followed. After the inter-
vention the control rate reached 67.7%. The incremental
effectiveness is equal to 15%. After intervention, the 
standard quarterly costs were lower for both groups
control and non-control: respectively €118.9 vs €152.7
and €359.9 vs €264.8. The overall rate of quarterly
savings after intervention compared to the situation
without intervention is equal to 32.4% (€172.1 versus
€255.2). CONCLUSION: The “pragmatic” evaluation of
the management of asthma in primary care with “trickle”
inclusions and follow-ups requires a new statistical
approach. This 1st primary network in France is a suc-
cessful experiment. (1) CMAJ. Nov 30, 1999; 161 (11
suppl).
